Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.

[1]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[2]  R. Woolson,et al.  The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials. , 2009, Journal of substance abuse treatment.

[3]  H. Jørgensen,et al.  Effectiveness of second generation antipsychotics: A systematic review of randomized trials , 2008, BMC psychiatry.

[4]  L. Hranov,et al.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.

[5]  Dan J Stein,et al.  World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia , 2008, Schizophrenia Research.

[6]  Alexander L. Miller,et al.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. , 2007, The Journal of clinical psychiatry.

[7]  C. Adams,et al.  Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine , 2007, BMJ : British Medical Journal.

[8]  J. Lieberman,et al.  Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.

[9]  Alexander L. Miller,et al.  Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. , 2007, The American journal of psychiatry.

[10]  D. Robinson,et al.  Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. , 2006, The American journal of psychiatry.

[11]  S. Hasan,et al.  Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. , 2006, The British journal of psychiatry : the journal of mental science.

[12]  R. Mcquade,et al.  Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine , 2006, Psychopharmacology.

[13]  Benedicto Crespo-Facorro,et al.  A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. , 2006, The Journal of clinical psychiatry.

[14]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[15]  J. Lieberman,et al.  Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. , 2006, The American journal of psychiatry.

[16]  H. Ascher-Svanum,et al.  Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  Stefan Leucht,et al.  Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. , 2006, The American journal of psychiatry.

[18]  D. Ames,et al.  A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration , 2006, International journal of geriatric psychiatry.

[19]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[20]  R. Califf,et al.  The case for practical clinical trials in psychiatry. , 2005, The American journal of psychiatry.

[21]  Alexander L. Miller,et al.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. , 2004, The Journal of clinical psychiatry.

[22]  C. Adams,et al.  Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine , 2003, BMJ : British Medical Journal.

[23]  D. Ames,et al.  The impact upon extra‐pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia , 2003, International journal of geriatric psychiatry.

[24]  J. Mullen,et al.  A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. , 2001, Clinical therapeutics.

[25]  V. Carey,et al.  Mixed-Effects Models in S and S-Plus , 2001 .

[26]  E. Lindström,et al.  Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat) , 2001, Nordic journal of psychiatry.

[27]  W. Fleischhacker,et al.  Selection bias in clinical trials with antipsychotics. , 2000, Journal of clinical psychopharmacology.

[28]  S Pollack,et al.  Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. , 1996, Journal of clinical psychopharmacology.

[29]  Jean Addington,et al.  A depression rating scale for schizophrenics , 1990, Schizophrenia Research.

[30]  Alexander L. Miller,et al.  The Mount Sinai conference on the pharmacotherapy of schizophrenia. , 2002, Schizophrenia bulletin.

[31]  J. Jerrell.  Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. , 2002, Schizophrenia bulletin.

[32]  R. Drake,et al.  Assessing substance use disorder in persons with severe mental illness. , 1996, New directions for mental health services.

[33]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[34]  J. Davis,et al.  Dose equivalence of the antipsychotic drugs. , 1974, Journal of psychiatric research.